GO45322: A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES
- Title
- A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES
- Principal Investigator
- Jiang, Bei
- Phase
- II
- Age Group
- Adult
- Applicable Disease Sites
- Breast Cancer
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Emily Hawkins, BSN
- Research Nurse
- Phone: +1 304-293-7375
- Email: eswiger1@hsc.wvu.edu